Giovannoni G, et al. Treatment outcomes of daclizumab in patients at high risk of transitioning to secondary progressive multiple sclerosis in DECIDE. EAN 2107, O2113.
Dabrafenib plus trametinib bij BRAFV600E-gemuteerd laag- en hooggradig glioom
feb 2022 | Neuro-oncologie